×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
RVNC – revance therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
RVNC
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
2/7
03:46 pm
rvnc
Crown Laboratories Completes Acquisition of Revance Therapeutics
Neutral
Report
Crown Laboratories Completes Acquisition of Revance Therapeutics
2/7
01:06 pm
rvnc
Class Action Filed Against Revance Therapeutics, Inc. (RVNC) Seeking Recovery for Investors – Contact Levi & Korsinsky
Neutral
Report
Class Action Filed Against Revance Therapeutics, Inc. (RVNC) Seeking Recovery for Investors – Contact Levi & Korsinsky
2/7
05:45 am
rvnc
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 4, 2025 in Revance Lawsuit - RVNC
Neutral
Report
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 4, 2025 in Revance Lawsuit - RVNC
2/6
04:00 pm
rvnc
RVNC INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Revance Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Neutral
Report
RVNC INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Revance Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
2/6
01:42 pm
rvnc
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Revance Therapeutics, Inc. (RVNC) Shareholders
Neutral
Report
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Revance Therapeutics, Inc. (RVNC) Shareholders
2/6
12:00 pm
rvnc
Revance Therapeutics, Inc. (RVNC) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Neutral
Report
Revance Therapeutics, Inc. (RVNC) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
2/6
08:39 am
rvnc
Crown Laboratories Announces Completion of Acquisition of Revance Therapeutics
Neutral
Report
Crown Laboratories Announces Completion of Acquisition of Revance Therapeutics
2/6
05:45 am
rvnc
The Gross Law Firm Notifies Shareholders of Revance Therapeutics, Inc.(RVNC) of a Class Action Lawsuit and an Upcoming Deadline
Neutral
Report
The Gross Law Firm Notifies Shareholders of Revance Therapeutics, Inc.(RVNC) of a Class Action Lawsuit and an Upcoming Deadline
Date
Time
Symbol
Headline
Impact
2/6
08:07 pm
rvnc
Form 4 Revance Therapeutics, For: Feb 04 Filed by: Gangolli Julian S
Neutral
Report
Form 4 Revance Therapeutics, For: Feb 04 Filed by: Gangolli Julian S
2/6
06:19 pm
rvnc
Form SCHEDULE 13G Revance Therapeutics, Filed by: GLAZER CAPITAL, LLC
Neutral
Report
Form SCHEDULE 13G Revance Therapeutics, Filed by: GLAZER CAPITAL, LLC
2/6
03:59 pm
rvnc
Form 4 Revance Therapeutics, For: Feb 04 Filed by: Moxie Dwight
Neutral
Report
Form 4 Revance Therapeutics, For: Feb 04 Filed by: Moxie Dwight
2/6
03:59 pm
rvnc
Form 4 Revance Therapeutics, For: Feb 04 Filed by: Foley Mark J
Neutral
Report
Form 4 Revance Therapeutics, For: Feb 04 Filed by: Foley Mark J
2/6
03:59 pm
rvnc
Form 4 Revance Therapeutics, For: Feb 04 Filed by: Schilke Tobin
Neutral
Report
Form 4 Revance Therapeutics, For: Feb 04 Filed by: Schilke Tobin
2/6
03:58 pm
rvnc
Form 4 Revance Therapeutics, For: Feb 04 Filed by: Hollander David
Neutral
Report
Form 4 Revance Therapeutics, For: Feb 04 Filed by: Hollander David
2/6
03:57 pm
rvnc
Form 4 Revance Therapeutics, For: Feb 04 Filed by: Jordan Erica
Neutral
Report
Form 4 Revance Therapeutics, For: Feb 04 Filed by: Jordan Erica
2/6
03:56 pm
rvnc
Form 4 Revance Therapeutics, For: Feb 04 Filed by: Ware Olivia C
Neutral
Report
Form 4 Revance Therapeutics, For: Feb 04 Filed by: Ware Olivia C
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
1/9
Revance to Participate in the 38th Annual J.P. Morgan Healthcare Conference
18.3%
5/9 Revance Therapeutics, Inc. (RVNC) on Q1 2019 Results - Earnings Call Transcript [Seeking Alpha] 16.5%
10/14 Revance Appoints Mark J. Foley as President and CEO, Replacing Dan Browne 15.1%
4/2 Revance Therapeutics Inc (NASDAQ: RVNC) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 8.4%
12/2 Revance Therapeutics Inc (NASDAQ: RVNC) is now covered by analysts at Goldman Sachs Group Inc. They set a "buy" rating and a $25.00 price target on the stock. 8.2%
1/11 Did Changing Sentiment Drive Revance Therapeutics's (NASDAQ:RVNC) Share Price Down By 25%? [Yahoo! Finance News] 7.7%
8/8 Revance Therapeutics Inc (NASDAQ: RVNC) had its "outperform" rating re-affirmed by analysts at William Blair. 7.2%
1/15 Revance Therapeutics Inc (NASDAQ: RVNC) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $24.00 price target on the stock. 5.3%
10/15 Form 8-K Revance Therapeutics, For: Oct 11 4.7%
7/29 Revance to Release Second Quarter 2019 Financial Results on Monday, August 5, 2019 4.6%
5/9 Revance Therapeutics, Inc. (RVNC) on Q1 2019 Results - Earnings Call Transcript [Seeking Alpha] 16.5%
10/14 Revance Appoints Mark J. Foley as President and CEO, Replacing Dan Browne 15.1%
4/2 Revance Therapeutics Inc (NASDAQ: RVNC) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 8.4%
12/2 Revance Therapeutics Inc (NASDAQ: RVNC) is now covered by analysts at Goldman Sachs Group Inc. They set a "buy" rating and a $25.00 price target on the stock. 8.2%
1/11 Did Changing Sentiment Drive Revance Therapeutics's (NASDAQ:RVNC) Share Price Down By 25%? [Yahoo! Finance News] 7.7%
8/8 Revance Therapeutics Inc (NASDAQ: RVNC) had its "outperform" rating re-affirmed by analysts at William Blair. 7.2%
1/15 Revance Therapeutics Inc (NASDAQ: RVNC) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $24.00 price target on the stock. 5.3%
10/15 Form 8-K Revance Therapeutics, For: Oct 11 4.7%
7/29 Revance to Release Second Quarter 2019 Financial Results on Monday, August 5, 2019 4.6%
TOP News Decliners
4/1
Revance Therapeutics Inc (NASDAQ: RVNC) had its "buy" rating re-affirmed by analysts at Mizuho. They now have a $35.00 price target on the stock.
-14.9%
12/3 Revance Announces Proposed Public Offering of Common Stock -14.6%
3/17 Form 4 Revance Therapeutics, For: Mar 15 Filed by: Joshi Abhay -13.7%
3/13 Form SC 13G Revance Therapeutics, Filed by: GIC Private Ltd -12.0%
2/25 Revance Therapeutics Inc (NASDAQ: RVNC) had its price target raised by analysts at Needham & Company LLC from $32.00 to $36.00. They now have a "buy" rating on the stock. -9.6%
2/10 Form 8-K Revance Therapeutics, For: Feb 10 -9.2%
4/15 Revance Therapeutics Inc (NASDAQ: RVNC) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $36.00 price target on the stock. -7.3%
2/26 Form 10-K Revance Therapeutics, For: Dec 31 -7.2%
4/30 Revance to Release First Quarter 2020 Financial Results on Thursday, May 7, 2020 -6.5%
8/27 Form 8-K Revance Therapeutics, For: Aug 22 -6.1%
12/3 Revance Announces Proposed Public Offering of Common Stock -14.6%
3/17 Form 4 Revance Therapeutics, For: Mar 15 Filed by: Joshi Abhay -13.7%
3/13 Form SC 13G Revance Therapeutics, Filed by: GIC Private Ltd -12.0%
2/25 Revance Therapeutics Inc (NASDAQ: RVNC) had its price target raised by analysts at Needham & Company LLC from $32.00 to $36.00. They now have a "buy" rating on the stock. -9.6%
2/10 Form 8-K Revance Therapeutics, For: Feb 10 -9.2%
4/15 Revance Therapeutics Inc (NASDAQ: RVNC) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $36.00 price target on the stock. -7.3%
2/26 Form 10-K Revance Therapeutics, For: Dec 31 -7.2%
4/30 Revance to Release First Quarter 2020 Financial Results on Thursday, May 7, 2020 -6.5%
8/27 Form 8-K Revance Therapeutics, For: Aug 22 -6.1%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: